Cumberland says ifetroban is well tolerated in systemic sclerosis trial
- Cumberland Pharmaceuticals reported Oct. 23, 2026, that ifetroban was generally well tolerated in its Phase 2a systemic sclerosis trial.
- The 12-month trial included 31 ifetroban recipients versus 10 placebo recipients; its size and exploratory analysis preclude efficacy conclusions.
- Gastrointestinal adverse events were more frequent with ifetroban; bleeding-related events increased modestly, with most events in both categories mild.
- No serious adverse event during treatment was assessed as related to the study drug.
- Biomarker studies and cardiac imaging evaluations will inform further development decisions; submission of the clinical study report to the FDA is planned.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001087294-26-000086), on November 16, 2026, and is solely responsible for the information contained therein.